Biotechnology Daily
more-
Moderna’s mRNA flu shot struggles to prove its worth again in phase 3 trial
Moderna’s first seasonal flu vaccine continues to underwhelm with the mRNA giant revealing that the…
BD launches ultrasound probe for guiding IV needles
HI-Bio’s expectations elevated after pair of phase 2 readouts bolster autoimmune ambitions
C2N’s amyloid- and tau-detecting Alzheimer’s blood test outperforms other screening tools in 2 studies
Biotech leaders ‘cannot stay quiet’ as judge blocks abortion pill approval
Market Watch
more-
Gold drifts lower as traders gauge Fed’s rate path
Gold futures edged lower Wednesday, stuck in a tight trading range as investors await further…
Polymetal International rises Tuesday, outperforms market
Big Tech’s added bulk in S&P 500 in 2023 outweighs index’s energy sector, DataTrek says
Coya Therapeutics stock gains on new data from Alzheimer’s study
Palantir’s stock surges toward 17-month on news of special-ops contract valued at up to $463 million
Bio Business News
more
Ultima Genomics combines ‘$100 genome’ tech with Genome Insight’s AI-powered analysis
After bursting out of stealth last year with the landscape-shifting…
Chasing Pfizer and Roche, Regenxbio benefits from FDA boost for DMD gene therapy
The FDA has boosted Regenxbio’s attempt to move five adeno-associated…
Genexine’s anemia drug matches Roche-CSL product in phase 3, laying groundwork for Asia filings
Genexine has laid down a marker in its bid to…
World News
more
Stocks close with a round of records, Dow clinches 35,000
U.S. stocks swept to another round of records Monday as…
Equifax stock surges toward biggest gain in 12 years after ‘impressive’ business update
Shares of Equifax Inc. EFX, +7.84% shot up 9.3% into…
SpaceX Starlink wins permit to send internet to customers like you
SpaceX has been busy building its Starlink satellite constellation. To…
Moderna’s mRNA flu shot struggles to prove its worth again in phase 3 trial
BD launches ultrasound probe for guiding IV needles
HI-Bio’s expectations elevated after pair of phase 2 readouts bolster autoimmune ambitions
C2N’s amyloid- and tau-detecting Alzheimer’s blood test outperforms other screening tools in 2 studies
Ultima Genomics combines ‘$100 genome’ tech with Genome Insight’s AI-powered analysis
Chasing Pfizer and Roche, Regenxbio benefits from FDA boost for DMD gene therapy
Genexine’s anemia drug matches Roche-CSL product in phase 3, laying groundwork for Asia filings
Regeneron expects $56M IPR&D charge tied to cell therapy pact
Gold drifts lower as traders gauge Fed’s rate path
Polymetal International rises Tuesday, outperforms market